Ignyta Gains EAP Designation and CE Marking for its Trailblaze Pharos Assay

Ignyta has received expedited access pathway designation from the FDA and CE marking for its Trailblaze Pharos companion diagnostic test service.

The assay will be used as an aid in selecting patients with solid tumors that have a gene rearrangement in certain DNA proteins. — Cynthia Jessup